Blockade of the TGF-β pathway by galunisertib inhibits the glial-mesenchymal transition in Müller glial cells

Aging increases the risks for developing fibrocontractile membranes on the retina, which causes significant macular distortion, as in the idiopathic epiretinal membrane (iERM). Retinal Müller glial cells are components of these membranes and may play a key role in the iERM pathogenesis. The transfor...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Experimental eye research 2023-01, Vol.226, p.109336-109336, Article 109336
Hauptverfasser: da Silva, Rafael André, Roda, Vinicius Moraes de Paiva, Akamine, Priscilla Sayami, da Silva, Daniela Simões, Siqueira, Paula Veloso, Matsuda, Monique, Hamassaki, Dânia Emi
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 109336
container_issue
container_start_page 109336
container_title Experimental eye research
container_volume 226
creator da Silva, Rafael André
Roda, Vinicius Moraes de Paiva
Akamine, Priscilla Sayami
da Silva, Daniela Simões
Siqueira, Paula Veloso
Matsuda, Monique
Hamassaki, Dânia Emi
description Aging increases the risks for developing fibrocontractile membranes on the retina, which causes significant macular distortion, as in the idiopathic epiretinal membrane (iERM). Retinal Müller glial cells are components of these membranes and may play a key role in the iERM pathogenesis. The transforming growth factor-β (TGF-β) induces Müller cell transdifferentiation into myofibroblast, reducing glial cell markers (glutamine synthetase, GS, and glial fibrillary acidic protein, GFAP) and increasing α-smooth muscle actin (α-SMA). Our aim was to investigate the effect of the TGF-β inhibitor galunisertib (LY2157299) on the glial-mesenchymal transition and contraction of Müller cells. MIO-M1 human Müller cells were treated with TGF-β1 (10 ng/mL), galunisertib (5, 10 and 20 μM) and TGF-β1+galunisertib for 24h and 48h. Galunisertib cytotoxicity was analyzed by MTT and trypan blue, and TGF-β1 blockade by phospho-SMAD3 immunofluorescence. Caspase-3 (cell death indicator), GS, GFAP and α-SMA expression was examined by immunofluorescence, Western blotting, and qPCR analysis. Cell contractility was determined by collagen gel contraction assay with Müller cells incorporated. Galunisertib did not show cytotoxicity at the concentrations evaluated and maintained the Müller cells phenotype, ensuring the GS expression. Galunisertib inhibited the TGF-β1 pathway by decreasing phospho-SMAD3 immunoreactivity, attenuated the α-SMA expression, and prevented the contraction of Müller cells in collagen gel. Although more studies are needed, in vitro assays suggest that galunisertib may be a potential candidate to attenuate the formation of fibrocontractile membranes and prevent retinal detachment and consequent loss of vision. •TGF-β signaling induces glial-mesenchymal transition.•Galunisertib inhibits TGF-β-induced glial-mesenchymal transition and Müller cell contraction.•Galunisertib may be a potential candidate to attenuate the formation of fibrocontractile membranes.
doi_str_mv 10.1016/j.exer.2022.109336
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2746391182</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0014483522004171</els_id><sourcerecordid>2746391182</sourcerecordid><originalsourceid>FETCH-LOGICAL-c271t-da88d2d8834dca5c7cc666d2c2fb307fbf8c77c49d98a01782d695879b65823d3</originalsourceid><addsrcrecordid>eNp9kL1uFDEURi0EIsvCC6RALmlm8c-M7ZFoQkQCUlCapLY89p2sN56Zje0F9rVSp6PnmeJlAmWqa12d79P1QeiYkhUlVHzcrOAXxBUjjJVFy7l4gRblISpCiHyJFoTQuqoVb47Qm5Q2ZctrWb9GR1zUTSNks0DT5zDZW-MATz3Oa8BX52fVn3u8NXn90-xxt8c3JuxGnyBm32E_rn3nc_rL3gRvQjVAgtGu94MJOEczJp_9NBYSf__9EALEmcMWQkhv0avehATvnuYSXZ99uTr9Wl1cnn87PbmoLJM0V84o5ZhTitfOmsZKa4UQjlnWd5zIvuuVldLWrWuVIVQq5kTbKNl2olGMO75EH-bebZzudpCyHnw6XGBGmHZJM1kL3lJa4CViM2rjlFKEXm-jH0zca0r0QbTe6INofRCtZ9El9P6pf9cN4P5H_pktwKcZgPLLH77Ek_XFEzgfwWbtJv9c_yOkM5FQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2746391182</pqid></control><display><type>article</type><title>Blockade of the TGF-β pathway by galunisertib inhibits the glial-mesenchymal transition in Müller glial cells</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>da Silva, Rafael André ; Roda, Vinicius Moraes de Paiva ; Akamine, Priscilla Sayami ; da Silva, Daniela Simões ; Siqueira, Paula Veloso ; Matsuda, Monique ; Hamassaki, Dânia Emi</creator><creatorcontrib>da Silva, Rafael André ; Roda, Vinicius Moraes de Paiva ; Akamine, Priscilla Sayami ; da Silva, Daniela Simões ; Siqueira, Paula Veloso ; Matsuda, Monique ; Hamassaki, Dânia Emi</creatorcontrib><description>Aging increases the risks for developing fibrocontractile membranes on the retina, which causes significant macular distortion, as in the idiopathic epiretinal membrane (iERM). Retinal Müller glial cells are components of these membranes and may play a key role in the iERM pathogenesis. The transforming growth factor-β (TGF-β) induces Müller cell transdifferentiation into myofibroblast, reducing glial cell markers (glutamine synthetase, GS, and glial fibrillary acidic protein, GFAP) and increasing α-smooth muscle actin (α-SMA). Our aim was to investigate the effect of the TGF-β inhibitor galunisertib (LY2157299) on the glial-mesenchymal transition and contraction of Müller cells. MIO-M1 human Müller cells were treated with TGF-β1 (10 ng/mL), galunisertib (5, 10 and 20 μM) and TGF-β1+galunisertib for 24h and 48h. Galunisertib cytotoxicity was analyzed by MTT and trypan blue, and TGF-β1 blockade by phospho-SMAD3 immunofluorescence. Caspase-3 (cell death indicator), GS, GFAP and α-SMA expression was examined by immunofluorescence, Western blotting, and qPCR analysis. Cell contractility was determined by collagen gel contraction assay with Müller cells incorporated. Galunisertib did not show cytotoxicity at the concentrations evaluated and maintained the Müller cells phenotype, ensuring the GS expression. Galunisertib inhibited the TGF-β1 pathway by decreasing phospho-SMAD3 immunoreactivity, attenuated the α-SMA expression, and prevented the contraction of Müller cells in collagen gel. Although more studies are needed, in vitro assays suggest that galunisertib may be a potential candidate to attenuate the formation of fibrocontractile membranes and prevent retinal detachment and consequent loss of vision. •TGF-β signaling induces glial-mesenchymal transition.•Galunisertib inhibits TGF-β-induced glial-mesenchymal transition and Müller cell contraction.•Galunisertib may be a potential candidate to attenuate the formation of fibrocontractile membranes.</description><identifier>ISSN: 0014-4835</identifier><identifier>EISSN: 1096-0007</identifier><identifier>DOI: 10.1016/j.exer.2022.109336</identifier><identifier>PMID: 36455675</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Actins - metabolism ; Collagen - metabolism ; Ependymoglial Cells - metabolism ; Epiretinal Membrane - metabolism ; Galunisertib ; Glial-mesenchymal transition ; Humans ; Müller cell ; Neuroglia - metabolism ; TGF-β ; Transforming Growth Factor beta - metabolism ; Transforming Growth Factor beta1 - metabolism ; Transforming Growth Factor beta1 - pharmacology</subject><ispartof>Experimental eye research, 2023-01, Vol.226, p.109336-109336, Article 109336</ispartof><rights>2022 Elsevier Ltd</rights><rights>Copyright © 2022 Elsevier Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c271t-da88d2d8834dca5c7cc666d2c2fb307fbf8c77c49d98a01782d695879b65823d3</citedby><cites>FETCH-LOGICAL-c271t-da88d2d8834dca5c7cc666d2c2fb307fbf8c77c49d98a01782d695879b65823d3</cites><orcidid>0000-0002-4351-6002</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.exer.2022.109336$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3548,27923,27924,45994</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36455675$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>da Silva, Rafael André</creatorcontrib><creatorcontrib>Roda, Vinicius Moraes de Paiva</creatorcontrib><creatorcontrib>Akamine, Priscilla Sayami</creatorcontrib><creatorcontrib>da Silva, Daniela Simões</creatorcontrib><creatorcontrib>Siqueira, Paula Veloso</creatorcontrib><creatorcontrib>Matsuda, Monique</creatorcontrib><creatorcontrib>Hamassaki, Dânia Emi</creatorcontrib><title>Blockade of the TGF-β pathway by galunisertib inhibits the glial-mesenchymal transition in Müller glial cells</title><title>Experimental eye research</title><addtitle>Exp Eye Res</addtitle><description>Aging increases the risks for developing fibrocontractile membranes on the retina, which causes significant macular distortion, as in the idiopathic epiretinal membrane (iERM). Retinal Müller glial cells are components of these membranes and may play a key role in the iERM pathogenesis. The transforming growth factor-β (TGF-β) induces Müller cell transdifferentiation into myofibroblast, reducing glial cell markers (glutamine synthetase, GS, and glial fibrillary acidic protein, GFAP) and increasing α-smooth muscle actin (α-SMA). Our aim was to investigate the effect of the TGF-β inhibitor galunisertib (LY2157299) on the glial-mesenchymal transition and contraction of Müller cells. MIO-M1 human Müller cells were treated with TGF-β1 (10 ng/mL), galunisertib (5, 10 and 20 μM) and TGF-β1+galunisertib for 24h and 48h. Galunisertib cytotoxicity was analyzed by MTT and trypan blue, and TGF-β1 blockade by phospho-SMAD3 immunofluorescence. Caspase-3 (cell death indicator), GS, GFAP and α-SMA expression was examined by immunofluorescence, Western blotting, and qPCR analysis. Cell contractility was determined by collagen gel contraction assay with Müller cells incorporated. Galunisertib did not show cytotoxicity at the concentrations evaluated and maintained the Müller cells phenotype, ensuring the GS expression. Galunisertib inhibited the TGF-β1 pathway by decreasing phospho-SMAD3 immunoreactivity, attenuated the α-SMA expression, and prevented the contraction of Müller cells in collagen gel. Although more studies are needed, in vitro assays suggest that galunisertib may be a potential candidate to attenuate the formation of fibrocontractile membranes and prevent retinal detachment and consequent loss of vision. •TGF-β signaling induces glial-mesenchymal transition.•Galunisertib inhibits TGF-β-induced glial-mesenchymal transition and Müller cell contraction.•Galunisertib may be a potential candidate to attenuate the formation of fibrocontractile membranes.</description><subject>Actins - metabolism</subject><subject>Collagen - metabolism</subject><subject>Ependymoglial Cells - metabolism</subject><subject>Epiretinal Membrane - metabolism</subject><subject>Galunisertib</subject><subject>Glial-mesenchymal transition</subject><subject>Humans</subject><subject>Müller cell</subject><subject>Neuroglia - metabolism</subject><subject>TGF-β</subject><subject>Transforming Growth Factor beta - metabolism</subject><subject>Transforming Growth Factor beta1 - metabolism</subject><subject>Transforming Growth Factor beta1 - pharmacology</subject><issn>0014-4835</issn><issn>1096-0007</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kL1uFDEURi0EIsvCC6RALmlm8c-M7ZFoQkQCUlCapLY89p2sN56Zje0F9rVSp6PnmeJlAmWqa12d79P1QeiYkhUlVHzcrOAXxBUjjJVFy7l4gRblISpCiHyJFoTQuqoVb47Qm5Q2ZctrWb9GR1zUTSNks0DT5zDZW-MATz3Oa8BX52fVn3u8NXn90-xxt8c3JuxGnyBm32E_rn3nc_rL3gRvQjVAgtGu94MJOEczJp_9NBYSf__9EALEmcMWQkhv0avehATvnuYSXZ99uTr9Wl1cnn87PbmoLJM0V84o5ZhTitfOmsZKa4UQjlnWd5zIvuuVldLWrWuVIVQq5kTbKNl2olGMO75EH-bebZzudpCyHnw6XGBGmHZJM1kL3lJa4CViM2rjlFKEXm-jH0zca0r0QbTe6INofRCtZ9El9P6pf9cN4P5H_pktwKcZgPLLH77Ek_XFEzgfwWbtJv9c_yOkM5FQ</recordid><startdate>202301</startdate><enddate>202301</enddate><creator>da Silva, Rafael André</creator><creator>Roda, Vinicius Moraes de Paiva</creator><creator>Akamine, Priscilla Sayami</creator><creator>da Silva, Daniela Simões</creator><creator>Siqueira, Paula Veloso</creator><creator>Matsuda, Monique</creator><creator>Hamassaki, Dânia Emi</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-4351-6002</orcidid></search><sort><creationdate>202301</creationdate><title>Blockade of the TGF-β pathway by galunisertib inhibits the glial-mesenchymal transition in Müller glial cells</title><author>da Silva, Rafael André ; Roda, Vinicius Moraes de Paiva ; Akamine, Priscilla Sayami ; da Silva, Daniela Simões ; Siqueira, Paula Veloso ; Matsuda, Monique ; Hamassaki, Dânia Emi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c271t-da88d2d8834dca5c7cc666d2c2fb307fbf8c77c49d98a01782d695879b65823d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Actins - metabolism</topic><topic>Collagen - metabolism</topic><topic>Ependymoglial Cells - metabolism</topic><topic>Epiretinal Membrane - metabolism</topic><topic>Galunisertib</topic><topic>Glial-mesenchymal transition</topic><topic>Humans</topic><topic>Müller cell</topic><topic>Neuroglia - metabolism</topic><topic>TGF-β</topic><topic>Transforming Growth Factor beta - metabolism</topic><topic>Transforming Growth Factor beta1 - metabolism</topic><topic>Transforming Growth Factor beta1 - pharmacology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>da Silva, Rafael André</creatorcontrib><creatorcontrib>Roda, Vinicius Moraes de Paiva</creatorcontrib><creatorcontrib>Akamine, Priscilla Sayami</creatorcontrib><creatorcontrib>da Silva, Daniela Simões</creatorcontrib><creatorcontrib>Siqueira, Paula Veloso</creatorcontrib><creatorcontrib>Matsuda, Monique</creatorcontrib><creatorcontrib>Hamassaki, Dânia Emi</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Experimental eye research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>da Silva, Rafael André</au><au>Roda, Vinicius Moraes de Paiva</au><au>Akamine, Priscilla Sayami</au><au>da Silva, Daniela Simões</au><au>Siqueira, Paula Veloso</au><au>Matsuda, Monique</au><au>Hamassaki, Dânia Emi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Blockade of the TGF-β pathway by galunisertib inhibits the glial-mesenchymal transition in Müller glial cells</atitle><jtitle>Experimental eye research</jtitle><addtitle>Exp Eye Res</addtitle><date>2023-01</date><risdate>2023</risdate><volume>226</volume><spage>109336</spage><epage>109336</epage><pages>109336-109336</pages><artnum>109336</artnum><issn>0014-4835</issn><eissn>1096-0007</eissn><abstract>Aging increases the risks for developing fibrocontractile membranes on the retina, which causes significant macular distortion, as in the idiopathic epiretinal membrane (iERM). Retinal Müller glial cells are components of these membranes and may play a key role in the iERM pathogenesis. The transforming growth factor-β (TGF-β) induces Müller cell transdifferentiation into myofibroblast, reducing glial cell markers (glutamine synthetase, GS, and glial fibrillary acidic protein, GFAP) and increasing α-smooth muscle actin (α-SMA). Our aim was to investigate the effect of the TGF-β inhibitor galunisertib (LY2157299) on the glial-mesenchymal transition and contraction of Müller cells. MIO-M1 human Müller cells were treated with TGF-β1 (10 ng/mL), galunisertib (5, 10 and 20 μM) and TGF-β1+galunisertib for 24h and 48h. Galunisertib cytotoxicity was analyzed by MTT and trypan blue, and TGF-β1 blockade by phospho-SMAD3 immunofluorescence. Caspase-3 (cell death indicator), GS, GFAP and α-SMA expression was examined by immunofluorescence, Western blotting, and qPCR analysis. Cell contractility was determined by collagen gel contraction assay with Müller cells incorporated. Galunisertib did not show cytotoxicity at the concentrations evaluated and maintained the Müller cells phenotype, ensuring the GS expression. Galunisertib inhibited the TGF-β1 pathway by decreasing phospho-SMAD3 immunoreactivity, attenuated the α-SMA expression, and prevented the contraction of Müller cells in collagen gel. Although more studies are needed, in vitro assays suggest that galunisertib may be a potential candidate to attenuate the formation of fibrocontractile membranes and prevent retinal detachment and consequent loss of vision. •TGF-β signaling induces glial-mesenchymal transition.•Galunisertib inhibits TGF-β-induced glial-mesenchymal transition and Müller cell contraction.•Galunisertib may be a potential candidate to attenuate the formation of fibrocontractile membranes.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>36455675</pmid><doi>10.1016/j.exer.2022.109336</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0002-4351-6002</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 0014-4835
ispartof Experimental eye research, 2023-01, Vol.226, p.109336-109336, Article 109336
issn 0014-4835
1096-0007
language eng
recordid cdi_proquest_miscellaneous_2746391182
source MEDLINE; ScienceDirect Journals (5 years ago - present)
subjects Actins - metabolism
Collagen - metabolism
Ependymoglial Cells - metabolism
Epiretinal Membrane - metabolism
Galunisertib
Glial-mesenchymal transition
Humans
Müller cell
Neuroglia - metabolism
TGF-β
Transforming Growth Factor beta - metabolism
Transforming Growth Factor beta1 - metabolism
Transforming Growth Factor beta1 - pharmacology
title Blockade of the TGF-β pathway by galunisertib inhibits the glial-mesenchymal transition in Müller glial cells
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T22%3A53%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Blockade%20of%20the%20TGF-%CE%B2%20pathway%20by%20galunisertib%20inhibits%20the%20glial-mesenchymal%20transition%20in%20M%C3%BCller%20glial%20cells&rft.jtitle=Experimental%20eye%20research&rft.au=da%20Silva,%20Rafael%20Andr%C3%A9&rft.date=2023-01&rft.volume=226&rft.spage=109336&rft.epage=109336&rft.pages=109336-109336&rft.artnum=109336&rft.issn=0014-4835&rft.eissn=1096-0007&rft_id=info:doi/10.1016/j.exer.2022.109336&rft_dat=%3Cproquest_cross%3E2746391182%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2746391182&rft_id=info:pmid/36455675&rft_els_id=S0014483522004171&rfr_iscdi=true